ath434
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2022 (NCT05109091)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05864365 | Phase 2 | May 23, 2023 | Alterity Therapeutics |
| NCT05109091 | Phase 2 | Jan 31, 2022 | Alterity Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alterity Therapeutics | For profit | 2 | 2 | 1 | 2022 |
1 organizations
Page 1 / 1